Immune Responses in Prostate, Lung, Melanoma and Breast Cancer Patients Following Stereotactic Body Radiotherapy (SBRT), Intensity Modulated Radiotherapy (IMRT) or Brachytherapy
Last updated on April 2022Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- 20
Inclusion Criteria
- Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast Cancer
- Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast Cancer
Summary
- Conditions
- Breast Cancer
- Lung Cancer
- Melanoma
- Prostate Cancer
- Type
- Observational
- Design
- Observational Model: Cohort
- Time Perspective: Prospective
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Inclusion Criteria
- Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast Cancer
- Hormone Refractory, Metastatic Prostate Cancer, Lung Cancer, and Melanoma or Breast Cancer
Tracking Information
- NCT #
- NCT01777802
- Collaborators
- Not Provided
- Investigators
- Principal Investigator: Sean S Park, MD, PhD Mayo Clinic
- Sean S Park, MD, PhD Mayo Clinic